

Association of Genomic Domains in *BRCA1* and *BRCA2* with Prostate Cancer Risk and Aggressiveness



Vivek L. Patel¹, Evan L. Busch^{2,3}, Tara M. Friebe^{2,4}, Angel Cronin⁴, Goska Leslie⁵, Lesley McGuffog⁵, Julian Adlard⁶, Simona Agata⁷, Bjarni A. Agnarsson^{8,9}, Munaza Ahmed¹⁰, Kristiina Aittomäki¹¹, Elisa Alducci⁷, Irene L. Andrulis^{12,13}, Adalgeir Arason^{8,14}, Norbert Arnold¹⁵, Grazia Artioli¹⁶, Brita Arver¹⁷, Bernd Auber¹⁸, Jacopo Azzollini¹⁹, Judith Balmaña²⁰, Rosa B. Barkardottir^{8,14}, Daniel R. Barnes⁵, Alicia Barroso²¹, Daniel Barrowdale⁵, Muriel Belotti²², Javier Benitez^{23,24}, Birgitte Bertelsen²⁵, Marinus J. Blok²⁶, Istvan Bodrogi²⁷, Valérie Bonadona²⁸, Bernardo Bonanni²⁹, Davide Bondavalli²⁹, Susanne E. Boonen³⁰, Julika Borde^{31,32,33}, Ake Borg³⁴, Angela R. Bradbury³⁵, Angela Brady³⁶, Carole Brewer³⁷, Joan Brunet³⁸, Bruno Buecher²², Sandra S. Buys³⁹, Santiago Cabezas-Camarero⁴⁰, Trinidad Caldes⁴¹, Almuth Caliebe⁴², Maria A. Caligo⁴³, Mariarosaria Calvello²⁹, Ian G. Campbell^{44,45}, Ileana Carnevali⁴⁶, Estela Carrasco²⁰, Tsun L. Chan^{47,48}, Annie T.W. Chu⁴⁷, Wendy K. Chung⁴⁹, Kathleen B.M. Claes⁵⁰, GEMO Study Collaborators²², EMBRACE Collaborators⁵, Jackie Cook⁵¹, Laura Cortesi⁵², Fergus J. Couch⁵³, Mary B. Daly⁵⁴, Giuseppe Damante⁵⁵, Esther Darder³⁸, Rosemarie Davidson⁵⁶, Miguel de la Hoya⁴¹, Lara Della Puppa⁵⁷, Joe Dennis⁵, Orland Diez⁵⁸, Yuan Chun Ding⁵⁹, Nina Ditsch⁶⁰, Susan M. Domchek³⁵, Alan Donaldson⁶¹, Bernd Dworniczak⁶², Douglas F. Easton^{5,63}, Diana M. Eccles⁶⁴, Rosalind A. Eeles⁶⁵, Hans Ehrencrona⁶⁶, Bent Ejlersten⁶⁷, Christoph Engel^{68,69}, D. Gareth Evans^{70,71}, Laurence Faivre⁷², Ulrike Faust⁷³, Lídia Feliubadaló⁷⁴, Lenka Foretova⁷⁵, Florentia Fostira⁷⁶, George Fountzilas⁷⁷, Debra Frost⁵, Vanesa García-Barberán⁴¹, Pilar Garre⁴¹, Marion Gauthier-Villars²², Lajos Géczi²⁷, Andrea Gehrig⁷⁸, Anne-Marie Gerdes⁷⁹, Paul Gesta⁸⁰, Giuseppe Giannini⁸¹, Gord Glendon¹², Andrew K. Godwin⁸², David E. Goldgar⁸³, Mark H. Greene⁸⁴, Angelica M. Gutierrez-Barrera⁸⁵, Eric Hahnen^{32,33}, Ute Hamann⁸⁶, Jan Hauke^{31,32,33}, Natalie Herold^{31,32,33}, Frans B.L. Hogervorst⁸⁷, Ellen Honisch⁸⁸, John L. Hopper⁸⁹, Peter J. Hulick^{90,91}, KConFab Investigators^{44,45}, HEBON Investigators⁹², Louise Izatt⁹³, Agnes Jager⁹⁴, Paul James^{45,95}, Ramunas Janavicius⁹⁶, Uffe Birk Jensen⁹⁷, Thomas Dyrso Jensen⁹⁸, Oskar Th. Johannsson⁹⁹, Esther M. John¹⁰⁰, Vijai Joseph¹⁰¹, Eunyoung Kang¹⁰², Karin Kast¹⁰³, Johanna I. Kiiski¹⁰⁴, Sung-Won Kim¹⁰⁵, Zisun Kim¹⁰⁶, Kwang-Pil Ko¹⁰⁷, Irene Konstantopoulou⁷⁶, Gero Kramer¹⁰⁸, Lotte Krogh¹⁰⁹, Torben A. Kruse¹⁰⁹, Ava Kwong^{47,110,111}, Mirjam Larsen^{31,32,33}, Christine Lasset²⁸, Charlotte Lautrup¹¹², Conxi Lázaro⁷⁴, Jihyoun Lee¹¹³, Jong Won Lee¹¹⁴, Min Hyuk Lee¹¹³, Johannes Lemke¹¹⁵, Fabienne Lesueur^{22,116,117,118}, Annelie Liljegren¹⁷, Annika Lindblom^{119,120}, Patricia Llovet⁴¹, Adria Lopez-Fernández²⁰, Irene Lopez-Perolio⁴¹, Victor Lorca⁴¹, Jennifer T. Loud⁸⁴, Edmond S.K. Ma^{47,48}, Phuong L. Mai¹²¹, Siranoush Manoukian¹⁹, Veronique Mari¹²², Lynn Martin¹²³, Laura Matricardi⁷, Noura Mebirouk^{22,116,117,118}, Veronica Medici⁵², Hanne E.J. Meijers-Heijboer¹²⁴, Alfons Meindl⁶⁰, Arjen R. Mensenkamp¹²⁵, Clare Miller¹²⁶, Denise Molina Gomes¹²⁷, Marco Montagna⁷, Thea M. Mooij¹²⁸, Lidia Moserle⁷, Emmanuelle Mouret-Fourme²², Anna Marie Mulligan^{129,130}, Katherine L. Nathanson³⁵, Marie Navratilova⁷⁵, Heli Nevanlinna¹⁰⁴, Dieter Niederacher⁸⁹, Finn C. Cilius Nielsen²⁵, Liene Nikitina-Zake¹³¹, Kenneth Offit^{102,132}, Edith Olah¹³³, Olufunmilayo I. Olopade¹³⁴, Kai-Ren Ong¹³⁵, Ana Osorio^{23,24}, Claus-Eric Ott¹³⁶, Domenico Palli¹³⁷, Sue K. Park^{138,139,140}, Michael T. Parsons¹⁴¹, Inge Sokilde Pedersen¹⁴², Bernard Peissel¹⁹, Ana Peixoto¹⁴³, Pedro Pérez-Segura⁴⁰, Paolo Peterlongo¹⁴⁴, Annabeth Høgh Petersen⁹⁸, Mary E. Porteous¹⁴⁵, Miguel Angel Pujana¹⁴⁶, Paolo Radice¹⁴⁷, Juliane Ramser¹⁴⁸, Johanna Rantala¹⁴⁹, Muhammad U. Rashid^{86,150}, Kerstin Rhiem^{31,32,33}, Piera Rizzolo⁸¹, Mark E. Robson¹³², Matti A. Rookus¹²⁸, Caroline M. Rossing²⁵, Kathryn J. Ruddy¹⁵¹, Catarina Santos¹⁴³, Claire Saule²², Rosa Scarpitta¹⁵², Rita K. Schmutzler^{32,33}, Hélène Schuster¹⁵³, Leigha Senter¹⁵⁴, Caroline M. Seynaeve⁹⁴, Payal D. Shah³⁵, Priyanka Sharma¹⁵⁵, Vivian Y. Shin¹¹⁰, Valentina Silvestri⁸¹, Jacques Simard¹⁵⁶, Christian F. Singer¹⁵⁷, Anne-Bine Skytte⁹⁸, Katie Snape¹⁵⁸, Angela R. Solano¹⁵⁹, Penny Soucy¹⁵⁵, Melissa C. Southey^{160,161}, Amanda B. Spurdle¹⁴¹, Linda Steele⁵⁹, Doris Steinemann¹⁶², Dominique Stoppa-Lyonnet^{22,163,164}, Agostina Stradella¹⁶⁵, Lone Sunde⁹⁷, Christian Sutter¹⁶⁶, Yen Y. Tan¹⁶⁷, Manuel R. Teixeira^{143,168}, Soo Hwang Teo^{169,170}, Mads Thomassen¹⁰⁹, Maria Grazia Tibiletti⁴⁶, Marc Tischkowitz^{171,172}, Silvia Tognazzo⁷, Amanda E. Toland¹⁷³, Stefania Tommasi¹⁷⁴, Diana Torres^{86,175}, Angela Toss⁵², Alison H. Trainer⁹⁵, Nadine Tung¹⁷⁶, Christi J. van Asperen¹⁷⁷, Frederieke H. van der Baan¹²⁸

Downloaded from <http://aacrjournals.org/cancerres/article-pdf/80/3/624/2800448/624.pdf> by guest on 07 October 2022

Lizet E. van der Kolk⁸⁷, Rob B. van der Luijt¹⁷⁸, Liselotte P. van Hest¹⁷⁹, Liliana Varesco¹⁸⁰, Raymonda Varon-Mateeva¹³⁶, Alessandra Viel⁵⁷, Jeroen Vierstraete⁵⁰, Roberta Villa¹⁹, Anna von Wachenfeldt¹⁷, Philipp Wagner¹⁸¹, Shan Wang-Gohrke¹⁸², Barbara Wappenschmidt^{32,33}, Jeffrey N. Weitzel¹⁸³, Greet Wieme⁵⁰, Siddhartha Yadav¹⁵¹, Drakoulis Yannoukakos⁷⁶, Sook-Yee Yoon¹⁸⁴, Cristina Zanzottera¹⁹, Kristin K. Zorn¹²¹, Anthony V. D'Amico¹, Matthew L. Freedman⁴, Mark M. Pomerantz⁴, Georgia Chenevix-Trench¹⁴¹, Antonis C. Antoniou⁵, Susan L. Neuhausen⁵⁹, Laura Ottini⁸¹, Henriette Roed Nielsen¹⁰⁹, and Timothy R. Rebbeck^{2,4}

ABSTRACT

Pathogenic sequence variants (PSV) in *BRCA1* or *BRCA2* (*BRCA1/2*) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in *BRCA1/2* were associated with risk of overall prostate cancer or high grade (Gleason 8+) prostate cancer using an international sample of 65 *BRCA1* and 171 *BRCA2* male PSV carriers with prostate cancer, and 3,388 *BRCA1* and 2,880 *BRCA2* male PSV carriers without prostate cancer. PSVs in the 3' region of *BRCA2* (c.7914+) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001-c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25–2.52; $P = 0.001$], as well as elevated risk of Gleason 8+ prostate cancer (HR =

3.11; 95% CI, 1.63–5.95; $P = 0.001$). c.756-c.1000 was also associated with elevated prostate cancer risk (HR = 2.83; 95% CI, 1.71–4.68; $P = 0.00004$) and elevated risk of Gleason 8+ prostate cancer (HR = 4.95; 95% CI, 2.12–11.54; $P = 0.0002$). No genotype–phenotype associations were detected for PSVs in *BRCA1*. These results demonstrate that specific *BRCA2* PSVs may be associated with elevated risk of developing aggressive prostate cancer.

Significance: Aggressive prostate cancer risk in *BRCA2* mutation carriers may vary according to the specific *BRCA2* mutation inherited by the at-risk individual.

¹Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts. ²Harvard T.H. Chan School of Public Health, Boston, Massachusetts. ³Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ⁴Dana-Farber Cancer Institute, Boston, Massachusetts. ⁵Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. ⁶Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, United Kingdom. ⁷Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. ⁸Department of Pathology, Landspítali University Hospital, 101, Reykjavik, Iceland. ⁹School of Medicine, University of Iceland, Reykjavik, Iceland. ¹⁰North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom. ¹¹Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. ¹²Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada. ¹³Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. ¹⁴BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ¹⁵Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany. ¹⁶ULSS 3 Serenissima, U.O.C. Oncologia ed Ematologia Oncologica, Mirano, Venice, Italy. ¹⁷Department of Oncology, Karolinska Institutet, Stockholm, Sweden. ¹⁸Institute of Human Genetics, Hannover Medical School, Hannover, Germany. ¹⁹Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Istituto Nazionale dei Tumori di Milano, Milan, Italy. ²⁰High Risk and Cancer Prevention Group, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain. ²¹Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. ²²Service de Génétique, Institut Curie, Paris, France. ²³Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. ²⁴Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain. ²⁵Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ²⁶Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands. ²⁷Department of Chemotherapy, National Institute of Oncology, Budapest, Hungary. ²⁸Unité de Prévention et d'Épidémiologie Génétique, Centre Léon Bérard, Lyon, France. ²⁹Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy. ³⁰Clinical Genetic Unit, Department of Paediatrics, Zealand University Hospital, Roskilde,

Denmark. ³¹Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany. ³²Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. ³³Center for Hereditary Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany. ³⁴Department of Oncology, Lund University and Skåne University Hospital, Lund, Sweden. ³⁵Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. ³⁶North West Thames Regional Genetics Service, Kennedy Galton Centre, The North West London Hospitals NHS Trust, Middlesex, United Kingdom. ³⁷Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, United Kingdom. ³⁸Genetic Counseling Unit, Hereditary Cancer Program, IDIBGI (Institut d'Investigació Biomèdica de Girona), Catalan Institute of Oncology, CIBERONC, Girona, Spain. ³⁹Department of Medicine, Huntsman Cancer Institute, Salt Lake City, Utah. ⁴⁰Department of Oncology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain. ⁴¹Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. ⁴²Institute of Human Genetics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany. ⁴³Section of Molecular Genetics, Department of Laboratory Medicine, University Hospital of Pisa, Pisa, Italy. ⁴⁴Peter MacCallum Cancer Center, Melbourne, Victoria, Australia. ⁴⁵Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia. ⁴⁶UO Anatomia Patologica, Ospedale di Circolo-Università dell'Insubria, Varese, Italy. ⁴⁷Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Centre, Happy Valley, Hong Kong. ⁴⁸Department of Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong. ⁴⁹Departments of Pediatrics and Medicine, Columbia University, New York, New York. ⁵⁰Centre for Medical Genetics, Ghent University, Ghent, Belgium. ⁵¹Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, United Kingdom. ⁵²Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy. ⁵³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. ⁵⁴Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. ⁵⁵Department of Medical and Biological Sciences, University of Udine, Udine, Italy. ⁵⁶Department of Clinical Genetics, South Glasgow University Hospitals, Glasgow, United Kingdom. ⁵⁷Division of Functional Onco-genomics and Genetics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy. ⁵⁸Oncogenetics Group, Clinical and Molecular Genetics Area, Vall d'Hebron Institute of Oncology (VHIO), University Hospital, Barcelona, Spain. ⁵⁹Department of Population

Sciences, Beckman Research Institute of City of Hope, Duarte, California. ⁶⁰Department of Gynecology and Obstetrics, Ludwig Maximilian University of Munich, Munich, Germany. ⁶¹Clinical Genetics Department, St Michael's Hospital, Bristol, United Kingdom. ⁶²Institute of Human Genetics, University of Münster, Münster, Germany. ⁶³Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom. ⁶⁴Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. ⁶⁵Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. ⁶⁶Department of Clinical Genetics, Lund University Hospital, Lund, Sweden. ⁶⁷Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ⁶⁸Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. ⁶⁹LIFE - Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany. ⁷⁰Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health and Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom. ⁷¹Manchester Centre for Genomic Medicine, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust and Manchester Academic Health Science Centre, Manchester, United Kingdom. ⁷²Unité d'oncogénétique, Centre de Lutte Contre le Cancer, Centre Georges-François Leclerc, Dijon, France. ⁷³Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. ⁷⁴Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL (Bellvitge Biomedical Research Institute), Catalan Institute of Oncology, CIBERONC, Barcelona, Spain. ⁷⁵Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. ⁷⁶Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research "Demokritos", Athens, Greece. ⁷⁷Second Department of Medical Oncology, EUROME-DICA General Clinic of Thessaloniki, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. ⁷⁸Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University of Würzburg, Würzburg, Germany. ⁷⁹Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark. ⁸⁰Service Régional Oncogénétique Poitou-Charentes, CH Niort, Niort, France. ⁸¹Department of Molecular Medicine, University La Sapienza, Rome, Italy. ⁸²Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, Kansas. ⁸³Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah. ⁸⁴Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. ⁸⁵Department of Breast Medical Oncology and Clinical Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas. ⁸⁶Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁸⁷Family Cancer Clinic, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. ⁸⁸Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. ⁸⁹Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. ⁹⁰Center for Medical Genetics, NorthShore University HealthSystem, Evanston, Illinois. ⁹¹The University of Chicago Pritzker School of Medicine, Chicago, Illinois. ⁹²The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Coordinating center: The Netherlands Cancer Institute, Amsterdam, the Netherlands. ⁹³Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. ⁹⁴Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. ⁹⁵Parkville Familial Cancer Centre, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia. ⁹⁶Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania. ⁹⁷Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark. ⁹⁸Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark. ⁹⁹Department of Oncology, Landspítali University Hospital, Reykjavik, Iceland. ¹⁰⁰Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California. ¹⁰¹Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York. ¹⁰²Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea. ¹⁰³Department of Gynecology and Obstetrics, Technical University of Dresden, Dresden, Germany. ¹⁰⁴Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. ¹⁰⁵Department of Surgery, Daerim Saint Mary's Hospital, Seoul, Korea. ¹⁰⁶Department of Surgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea. ¹⁰⁷Department of Preventive Medicine, Gacheon University College of Medicine, Incheon, Republic of Korea. ¹⁰⁸Department of Urology, Medical University of Vienna, Vienna, Austria. ¹⁰⁹Department of Clinical Genetics, Odense University Hospital, Odense, Denmark. ¹¹⁰Department of Surgery, The University of Hong Kong, Pok Fu Lam, Hong Kong. ¹¹¹Department of Surgery, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong. ¹¹²Department of Clinical Genetics, Aalborg University Hospital, Aalborg, Denmark. ¹¹³Department of Surgery, Soonchunhyang University College of Medicine and Soonchunhyang University Hospital, Seoul, Korea. ¹¹⁴Department of Surgery, Ulsan University College of Medicine and Asan Medical Center, Seoul, Korea. ¹¹⁵Institute of Human Genetics, University Hospital Leipzig, Leipzig, Germany. ¹¹⁶Genetic Epidemiology of Cancer Team, Inserm U900, Paris, France. ¹¹⁷Institut Curie, Paris, France. ¹¹⁸Mines ParisTech, Fontainebleau, France. ¹¹⁹Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ¹²⁰Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. ¹²¹Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. ¹²²Département d'Hématologie-Oncologie Médicale, Centre Antoine Lacassagne, Nice, France. ¹²³Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. ¹²⁴Department of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands. ¹²⁵Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. ¹²⁶Department of Clinical Genetics, Alder Hey Hospital, Liverpool, United Kingdom. ¹²⁷Service de Biologie de la Reproduction, Cytogénétique et Génétique Médicale, CHI Poissy - Saint Germain, Poissy, France. ¹²⁸Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. ¹²⁹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. ¹³⁰Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada. ¹³¹Latvian Biomedical Research and Study Centre, Riga, Latvia. ¹³²Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. ¹³³Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. ¹³⁴Center for Clinical Cancer Genetics, The University of Chicago, Chicago, Illinois. ¹³⁵West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Birmingham, United Kingdom. ¹³⁶Institute for Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. ¹³⁷Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy. ¹³⁸Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea. ¹³⁹Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea. ¹⁴⁰Cancer Research Institute, Seoul National University, Seoul, Korea. ¹⁴¹Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ¹⁴²Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark. ¹⁴³Department of Genetics, Portuguese Oncology Institute, Porto, Portugal. ¹⁴⁴Genome Diagnostics Program, IFOM - the FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy. ¹⁴⁵South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, United Kingdom. ¹⁴⁶Translational Research Laboratory, IDIBELL (Bellvitge Biomedical Research Institute), Catalan Institute of Oncology, CIBERONC, Barcelona, Spain. ¹⁴⁷Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, in Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), Milan, Italy. ¹⁴⁸Division of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. ¹⁴⁹Clinical Genetics, Karolinska Institutet, Stockholm, Sweden. ¹⁵⁰Department of Basic Sciences, Shaikat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan. ¹⁵¹Department of Oncology, Mayo Clinic, Rochester, Minnesota. ¹⁵²Section of Genetic Oncology, Department of Laboratory Medicine, University and University Hospital of Pisa, Pisa, Italy. ¹⁵³Unité d'Oncogénétique, Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg, France. ¹⁵⁴Clinical Cancer Genetics Program, Division of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. ¹⁵⁵Department of Internal Medicine, Division of Oncology, University of Kansas Medical Center, Westwood, Kansas. ¹⁵⁶Genomics Center, Centre Hospitalier Universitaire de Québec - Université

Introduction

Inherited pathogenic sequence variants (PSV) in DNA repair pathway genes including *BRCA1* and *BRCA2* (*BRCA1/2*) are associated with prostate cancer risk and severity (1–15). Carriers of *BRCA2* PSVs have been reported to have increased levels of serum prostate-specific antigen (PSA) at diagnosis, increased proportion of high Gleason (7+) tumors, less favorable tumor stage, increased rates of nodal and distant metastases, and increased rate of recurrence after treatment (2, 11–18). *BRCA2* PSVs confer lower overall survival and prostate cancer-specific survival (13–15). Ashkenazi Jewish carriers of *BRCA1* PSVs have been reported to have elevated rates of Gleason 7+ tumors, higher rates of recurrence, and a 5-fold increase in prostate cancer death (5, 19), although the association of *BRCA1* and prostate cancer has not been replicated in all studies (20). Distinct tumor PSV, methylation, and expression patterns have been identified in *BRCA2* compared with non-*BRCA2*-mutant prostate tumors. These data suggest that *BRCA2*-mutant tumors have features that are more similar to metastatic castrate-resistant disease than localized prostate cancer (21–23).

Specific genotype–phenotype correlations have been reported (24), including *BRCA1/2*-associated breast and ovarian cancers (25–27), *APC* PSVs, and severity of familial adenomatous polyposis (28, 29), and *RET* PSVs in multiple endocrine neoplasia type 2 (MEN2) and familial medullary thyroid carcinoma (30). There have been suggestions in the literature that similar patterns exist for *BRCA1* or *BRCA2* and prostate cancer. Liede and colleagues (31) reported that early-onset prostate cancer (age <65 years) was more frequent in men with *BRCA2* PSVs outside of the ovarian cancer cluster region. More recently, Nielsen and colleagues (32), using a sample of 37 prostate cancer cases, 19 of whom had *BRCA2* PSVs, identified a region in *BRCA2* at c.6373–c.6492 in which PSVs were associated with an increased risk of prostate cancer.

We analyzed a large international cohort of 3,453 *BRCA1* and 3,051 *BRCA2* PSV male carriers to evaluate the distribution of germline PSVs in men diagnosed with prostate cancer and men without prior prostate cancer diagnosis. We hypothesized that specific PSVs in *BRCA1* or *BRCA2* might influence development of prostate cancer and be associated with prostate cancer severity.

Materials and Methods

Study sample

The Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) is an international collaboration of centers on 6 continents that has collected information about carriers of *BRCA1/2* PSVs (33). All carriers participated in clinical assessment and/or research studies at a participating institution after providing informed consent under protocols approved by local institutional review boards. Participants' ascertainment date was defined as the time of study interview (e.g., enrollment in a research study). Forty-eight centers and multicenter consortia (Supplementary Table S1) in 31 countries submitted deidentified data that met the CIMBA inclusion criteria as described previously. No races/ethnicities were excluded from this study. Self-reported race/ethnicity data were collected across the various centers using either fixed categories or open-ended questions.

We analyzed only male carriers with clearly pathogenic *BRCA1/2* PSVs that occurred 3' of nucleotide position 1 (A of the ATC translation initiation codon in either *BRCA1* and *BRCA2*). This excluded 101 males who had a PSV occurring 5' translation start site. Definitions of these PSVs are shown in Supplementary Table S2. PSVs were defined using CIMBA criteria as follows: (i) PSVs generating a premature termination codon, except those in exon 27 at or after codon 3310 of *BRCA2*; (ii) large in-frame deletions that spanned ≥ 1 exons; and (iii) deletions of transcription regulatory regions (promoter and/or first exon) expected to cause lack of mutant allele expression (33–35). We also included missense variants considered pathogenic as determined by using multifactorial likelihood approaches (35, 36). PSVs are described using the Human Genome Variation Society (HGVS) nomenclature (Supplementary Table S2).

Authors have obtained written informed consent.

PSV binning

To identify segments across the intronic and exonic regions of *BRCA1* and *BRCA2* associated with different prostate cancer risks, we created PSV bins by base pair location within each gene. These genomic sequence bins contained all PSVs regardless of category or function, except for large genomic rearrangements, which were

Laval, Research Centre, Québec City, Québec, Canada. ¹⁵⁷Dept of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. ¹⁵⁸Medical Genetics Unit, St George's, University of London, London, United Kingdom. ¹⁵⁹INBIOMED, Faculty of Medicine/CONICET and CEMIC, Department of Clinical Chemistry, Medical Direction, University of Buenos Aires, Buenos Aires, Argentina. ¹⁶⁰Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. ¹⁶¹Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia. ¹⁶²Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany. ¹⁶³Department of Tumour Biology, INSERM U830, Paris, France. ¹⁶⁴Université Paris Descartes, Paris, France. ¹⁶⁵Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL (Bellvitge Biomedical Research Institute), Catalan Institute of Oncology, CIBERONC, Barcelona, Spain. ¹⁶⁶Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany. ¹⁶⁷Department of OB/GYN, Medical University of Vienna, Vienna, Austria. ¹⁶⁸Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal. ¹⁶⁹Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia. ¹⁷⁰Breast Cancer Research Unit, Cancer Research Institute, University Malaya Medical Centre, Kuala Lumpur, Malaysia. ¹⁷¹Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montréal, Québec, Canada. ¹⁷²Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom. ¹⁷³Department of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio. ¹⁷⁴Istituto Nazionale Tumori 'Giovanni Paolo II, Bari, Italy. ¹⁷⁵Institute of Human Genetics, Pontificia Universidad Javeriana, Bogotá, Colombia. ¹⁷⁶Department of Med-

ical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. ¹⁷⁷Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands. ¹⁷⁸Department of Medical Genetics, University Medical Center, Utrecht, the Netherlands. ¹⁷⁹Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. ¹⁸⁰Unit of Hereditary Cancer, Department of Epidemiology, Prevention and Special Functions, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) AOU San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. ¹⁸¹Department of Women's Health, Tubingen University Hospital, Tubingen, Germany. ¹⁸²Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany. ¹⁸³Clinical Cancer Genetics, City of Hope, Duarte, California. ¹⁸⁴Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia.

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Corresponding Author: Timothy R. Rebbeck, Dana Farber Cancer Institute, 1101 Dana Building, 450 Brookline Ave, Boston, MA 02215. Phone: 617-632-6128; Fax: 617-632-2200; E-mail: Timothy_Rebbeck@dfci.harvard.edu

Cancer Res 2020;80:624–38

doi: 10.1158/0008-5472.CAN-19-1840

©2019 American Association for Cancer Research.

excluded from this analysis because they may span multiple bins. Bins were constructed in two ways. First, we used an algorithm in which each bin contained approximately equal numbers of participants (including all cases and controls) with bin length defined by distance in base pairs. Thus, bin length for common PSVs (e.g., the Icelandic founder PSV *c.771_775del*) were small compared with bins with a wider range of PSVs. We divided the number of PSVs across the span of *BRCA1* or *BRCA2* into deciles of PSVs observed in cases and noncases (i.e., “decile” bins). Second, we identified putative functional domains in *BRCA1* or *BRCA2* and created bins that captured these domains, as well as bins that contained no functional domain. These domains were determined by boundaries reported in the pfam database (37). The resulting bin boundaries are presented in Supplementary Table S3 and shown graphically in Fig. 1 for *BRCA1* and Fig. 2 for *BRCA2*. We chose to use these two binning methods based on our earlier published research (24) that indicated the inferences about mutation risk association differences were similar regardless of the binning approach used. After the initial evaluation across all bins (Supplementary Table S3), we further collapsed bins that were inferred to have homogeneous prostate cancer, either elevated above or not different from the reference bin.

PSV type and function

In addition to the binning analyses described above, we also considered whether the predicted type and function of heritable *BRCA1/2* PSVs in the CIMBA database were associated with prostate cancer. The definition of these PSV types and their functions are presented in Supplementary Table S2. PSVs were grouped by type and function as frameshift (FS), nonsense (NS), missense (MS), and splice site (SP; Supplementary Table S2). PSVs expected to generate stable or unstable, or no proteins were designated into previously reported classes 1, 2, or 3 (38–40). Missense PSVs in *BRCA1* were combined into one group that contained PSVs in the RING (41, 42) and BRCT domains (43–46). We compared PSVs predicted to produce nonsense-mediated decay (NMD) versus those that were not. PSVs predicted not to cause NMD were defined as those creating a stop codon within 50 nucleotides before or within the last exon (47). Premature termination codons comprised all PSVs leading to a truncated open-reading frame.

Statistical analysis

For the first set of analyses assessing all bins across the genes, a different reference group was defined for each combination of gene (*BRCA1* or *BRCA2*) and binning scheme (decile or functional). Reference bins were chosen based on analysis of each bin's association with prostate cancer compared with all other bins as a group and found to have the lowest hazard of prostate cancer for each gene. The reference bins used in each analysis are shown in Table 1. An exploration of other reference bins did not change the inferences of this analysis.

To estimate the relative hazards associated with each bin compared with the reference bin, we fitted Cox proportional hazards regression models separately in *BRCA1* and *BRCA2* PSV carriers. The primary outcomes of interest were diagnosis of prostate cancer (vs. no prostate cancer) or Gleason 8+ prostate cancer (vs. no prostate cancer) and Gleason ≤ 7 (vs. no prostate cancer). Time to event was computed from birth to age at prostate cancer diagnosis or age at ascertainment (which ever occurred first). No time or events were considered after time of ascertainment. All analyses were adjusted for confounding by race (African American vs. any other ethnicity) and birth cohort, defined as those born before or after median birth date of the total sample. We also adjusted all analyses by country of ascertainment. We computed

the prostate cancer HR for each defined bin relative to the common reference bin. To account for intracluster dependence due to multiple individuals from the same family, a robust sandwich variance estimate was specified in Cox proportional hazards models (48).

Hypothesis tests were judged to be statistically significant based on two-sided tests with $P < 0.05$. All P values were corrected for multiple hypothesis testing within each table of results by controlling the false discovery rate (FDR) using the method of Benjamini and Hochberg (49). Analyses were conducted in STATA v14, SPSS, or R version 2.7.2 (R Foundation for Statistical Computing).

Results

A total of 3,453 male *BRCA1* and 3,051 male *BRCA2* PSV carriers were eligible for analysis (see Table 2). The median prostate cancer diagnosis ages were 64 years in both *BRCA1* and *BRCA2* PSV carriers. Among *BRCA1/2* PSV carriers, 74% and 81%, respectively, self-reported their race as white.

BRCA1

As shown in Table 1, there were no statistically significant associations between PSVs in any *BRCA1* bin and elevated prostate cancer risk. There was also no association of *BRCA1* PSVs with Gleason 8+ disease with region.

BRCA2

In *BRCA2*, we identified a “prostate cancer cluster region” (PCCR) in which PSVs were associated with elevated prostate cancer risk. The risk estimates were obtained by considering all PSVs within the region of interest defined by the overlap of bins generated using the “decile” and functional binning methods described above. The PCCR included all PSVs 3' of *c.7914* and associated with HR = 1.78 [95% confidence interval (CI), 1.25–2.52; $P = 0.001$] when compared with PSVs in the reference bin *c.1001-c.7913* (Table 1). In addition, we identified a region bounded by *c.756* and *c.1000* (Supplementary Table S3; Fig. 2) that was associated with elevated prostate cancer risk with HR = 2.83 (95% CI, 1.71–4.68; $P = 4 \times 10^{-5}$) compared with PSVs in the reference bin *c.1001-c.7913*. This region contains the *c.771_775del* Icelandic founder PSV, which is the dominant PSV in this bin ($n = 92$ of 117 total PSVs in this bin). Comparison of the risk in carriers of *c.771_775del* to the risk in carriers of PSVs in *c.1001-c.7913* gave HR = 3.34 (95% CI, 2.01–5.55; $P = 3 \times 10^{-6}$). Because of the small number of carriers of other PSVs in this bin ($N = 25$), it was not possible to estimate risk of prostate cancer for carriers of the other (non-*c.771_775del*) PSVs in this bin. Risk of prostate cancer among those without a PCCR PSV was not elevated except for carriers of PSVs in bin 6 (*c.5910-c.6275*; HR = 2.83; 95% CI, 1.21–6.58; $P = 0.016$; Table 2). Both the PCCR and region *c.756-c.1000* were contained almost entirely within the previously identified breast cancer cluster regions (BCCR; ref. 24). Collectively, regions in which PSVs were associated with a significantly increased risk of prostate cancer development contained the *BRCA2* helical plasma domain, the oligonucleotide/oligosaccharide-binding domain 1 (OB1), the Tower domain (OB2), and the N-terminal PALB2-binding site (Fig. 2). Highest risk was associated with PSVs affecting OB1 and OB2 (Fig. 2).

Risk of high-grade prostate cancer (Gleason 8+) was even more strongly associated with PSVs in the PCCR (HR = 3.11; 95% CI, 1.63–5.95; $P = 0.001$; Table 1). A similar association was also observed for PSVs in the region containing the Icelandic founder PSV, *c.771_775del* (HR = 4.95; 95% CI, 2.12–11.54; $P = 2 \times 10^{-4}$), and




Figure 1.

BRCA1 PSV distribution. The x-axis displays the amino acid sequence of the *BRCA1* gene. The violet markers indicate the position of PSVs found in the *BRCA1* PSV carriers. The vertical position of the markers on the y-axis indicates the frequency of the PSV found in the cohort. In addition, the blue and tan bars with corresponding axis markers delineate the bins of the *BRCA1* PSVs that were created using the "decile" binning strategy and the "functional" binning strategy. Orange and light blue bars indicate the position of breast and ovarian cancer cluster regions, respectively, as identified in the CIMBA breast cancer cohort (Rebbeck et al.; ref. 24). Finally, known functional domains within the *BRCA1* gene are highlighted. **A**, Distribution of total *BRCA1* PSVs in carriers. **B**, Distribution of *BRCA1* PSVs in carriers who did not develop prostate cancer. **C**, Distribution of *BRCA1* PSVs in carriers who developed prostate cancer.

the c.771_775del PSV itself (HR = 5.66; 95% CI, 2.43–13.22; $P = 6 \times 10^{-5}$). Together, these regions were associated with increased Gleason 8+ prostate cancer risk (HR = 3.80; 95% CI, 2.10–6.89; $P = 1 \times 10^{-5}$). Risk of Gleason ≤ 7 prostate cancer was elevated for carriers of c.771_775del (HR = 3.29; 95% CI, 1.38–7.83; $P = 0.007$), but not elevated for those with PSVs in the PCCR (HR = 1.56; 95%CI, 0.88–2.78; $P = 0.130$; **Table 1**).

To ensure that the inferred effects were not due to the common Jewish founder PSV c.5946del that was included in the reference bin, we repeated calculations after excluding carriers these PSVs from the reference bin. After excluding these PSV carriers from the reference bin, the association with PSVs in the bin containing the c.771_775del and in the PCCR remained statistically significant (HR = 3.03; 95% CI, 1.83–5.04; $P = 2 \times 10^{-5}$ and HR = 1.89; 95%




Figure 2.

BRCA2 PSV distribution. The x-axis displays the amino acid sequence of the *BRCA2* gene. The violet markers indicate the position of PSVs found in the *BRCA2* PSV carriers. The vertical position of the markers on the y-axis indicates the frequency of the PSV found in the cohort. In addition, the blue and tan bars with corresponding axis markers delineate the bins of the *BRCA2* PSVs that were created using the "decile" binning strategy and the "functional" binning strategy. Orange and light blue bars indicate the position of breast and ovarian cancer cluster regions, respectively, as identified in the CIMBA breast cancer cohort (Rebbeck et al.; ref. 24). Finally, known functional domains within the *BRCA2* gene are highlighted. **A**, Distribution of total *BRCA2* PSVs in carriers. **B**, Distribution of *BRCA2* PSVs in carriers who did not develop prostate cancer. **C**, Distribution of *BRCA2* PSVs in carriers who developed prostate cancer.

Table 1. Association analyses of prostate cancer by bin for *BRCA1* and *BRCA2* PSVs.

BRCA1 – all prostate cancer						
Grouping	Bin	Nucleotide range	PC+	PC–	HR (95% CI)	P
BRCA1 Decile	1	≤c.81	11	339	1.06 (0.36–3.13)	0.917
	2	c.82–c.302	5	325	REF	
	3	c.303 – c.1504	4	331	0.82 (0.23–2.92)	0.761
	4	c.1505 – c.2475	8	431	1.09 (0.34–3.43)	0.888
	5	c.2476 – c.3319	3	274	0.33 (0.15–2.60)	0.526
	6	c.3320 – c.3710	5	308	1.32 (0.36–4.89)	0.677
	7	c.3711 – c.4065	9	318	1.96 (0.65–5.86)	0.230
	8	c.4066 – c.5030	1	333	0.16 (0.02–1.27)	0.084
	9	c.5031 – c.5266	13	425	1.68 (0.58–4.84)	0.339
	10	c.5267+	2	231	0.49 (0.10–2.49)	0.389
BRCA1 Functional	1	≤c.181	13	515	0.72 (0.34–1.53)	0.396
	2	c.182–c.1287	6	433	0.83 (0.32–2.20)	0.713
	3	c.1288–c.2475	9	478	0.93 (0.37–2.36)	0.887
	4	c.2476–c.3607	5	487	0.58 (0.19–1.75)	0.333
	5	c.3608–c.4183	12	462	1.19 (0.54–2.64)	0.671
	6	c.4184–c.5194	5	485	0.38 (0.12–1.25)	0.112
	7	c.5195+	11	455	REF	
BRCA2–All prostate cancer						
Grouping	Bin	Nucleotide range	PC+	PC–	HR (95% CI)	P
Decile	1	≤c.755	12	296	1.71 (0.66–4.46)	0.268
	2	c.756–c.1813	25	277	3.38 (1.24–9.19)	0.017
	3	c.1814–c.3530	6	293	REF	
	4	c.3531–c.4965	13	296	2.00 (0.69–5.76)	0.202
	5	c.4966–c.5909	13	307	2.14 (0.66–7.00)	0.207
	6	c.5910–c.6275	30	334	2.83 (1.21–6.58)	0.016
	7	c.6276–c.7007	12	214	2.69 (0.89–8.13)	0.079
	8	c.7008–c.7913	10	285	2.12 (0.60–7.42)	0.240
	9	c.7914–c.8953	26	281	3.32 (1.28–8.65)	0.014
	10	c.8954+	23	274	4.26 (1.60–11.37)	0.004
Functional	1	≤c.1000	27	398	1.39 (0.74–2.64)	0.307
	2	c.1001–c.3005	14	397	0.80 (0.39–1.63)	0.535
	3	c.3006–c.5172	16	408	REF	
	4	c.5173–c.6255	32	498	1.01 (0.53–1.93)	0.967
	5	c.6256–c.7436	24	400	1.44 (0.74–2.82)	0.286
	6	c.7437–c.8616	28	390	1.68 (0.91–3.13)	0.100
	7	c.8617+	29	366	1.64 (0.90–3.01)	0.106
Elevated vs. no elevated prostate cancer risk	1	≤c.755	12	296	0.73 (0.40–1.31)	0.288
	2 ^a	c.756–c.1000	15	102	2.83 (1.71–4.68)	4 × 10 ^{−5}
	3	c.1001–c.7913	94	1,904	REF	
Elevated vs. no elevated prostate cancer risk	PCCR	c.7914+	49	555	1.78 (1.25–2.52)	0.001
	No Elevated PCa Risk	≤c.755, c.1001–c.7913	106	2,200	REF	
	Elevated PCa risk	c.756–c.1000, c.7914+	65	657	2.02 (1.48–2.77)	9 × 10 ^{−6}
BRCA2–Prostate cancer by Gleason grade						
Gleason 8+	Bin	Nucleotide range	PC+	PC–	HR (95% CI)	P
Bins with elevated risk	1	≤c.755	2	299	0.53 (0.12–2.32)	0.399
	2	c.756–c.1000	6	108	4.95 (2.12–11.54)	2 × 10 ^{−4}
	3	c.1001–c.7913	19	1,940	REF	
	PCCR	c.7914+	18	572	3.11 (1.63–5.95)	0.001
Bins with elevated risk	No elevated PCa risk	≤c.755, c.1001–c.7913	21	2,239	REF	
	Elevated PCa risk	c.756–c.1000, c.7914+	24	680	3.80 (2.10–6.89)	1 × 10 ^{−5}
Gleason <7						
Bins with elevated risk	1	≤c.755	3	298	0.47 (0.14–1.57)	0.221
	2 ^a	c.756–c.1000	6	108	3.29 (1.38–7.83)	0.007
	3	c.1001–c.7913	36	1,923	REF	
	PCCR	c.7914+	17	573	1.56 (0.88–2.78)	0.130
Bins with elevated risk	No elevated PCa risk	≤c.755, c.1001–c.7913	39	2,221	REF	
	Elevated PCa risk	c.756–c.1000, c.7914+	23	681	1.89 (1.14–3.14)	0.014

Abbreviation: PCa, prostate cancer.

^aBin containing Icelandic Founder PSV c.771_775del.

Table 2. Characteristics of study participants.

	Total	Carriers of PSV in <i>BRCA1</i> N = 3,453 (%)	Carriers of PSV in <i>BRCA2</i> N = 3,051 (%)			
Region	Asia	76 (2.2)	90 (2.9)			
	Australia	386 (11.2)	292 (9.6)			
	Europe	2,287 (66.2)	2,165 (71.0)			
	North America	662 (19.2)	497 (16.3)			
	South America	42 (1.2)	7 (0.2)			
Self-identified Race/ethnicity	Caucasian	2,557 (74.1)	2,455 (80.5)			
	African American	20 (0.6)	14 (0.5)			
	Asian	76 (2.2)	101 (3.3)			
	Hispanic	54 (1.6)	16 (0.5)			
	Jewish	124 (3.6)	94 (3.1)			
	Other	45 (1.3)	10 (0.3)			
	Unknown	575 (16.7)	358 (11.7)			
Ascertainment	Clinic-based	3,352 (97.1)	2,969 (97.3)			
	Population-based	101 (2.9)	82 (2.7)			
PCa	Yes	65 (1.9)	171 (5.5)			
	No	3,388 (98.1)	2,880 (94.4)			
Gleason Score	≤6	16 (24.6)	32 (18.7)			
	7	9 (13.8)	30 (17.5)			
	8	3 (4.6)	16 (3.1)			
	9	7 (10.8)	26 (15.2)			
	10	0 (0.0)	5 (2.9)			
	Missing	30 (46.2)	62 (36.2)			
M Stage	M0	18 (27.7)	33 (19.3)			
	M1	2 (3.1)	14 (8.2)			
	MX	8 (12.3)	28 (16.4)			
	Missing	37 (56.9)	96 (56.1)			
Other cancer diagnosis	Yes	332 (9.6)	657 (21.5)			
	No	3,121 (90.4)	2,389 (78.5)			
	N	Median	Range	N	Median	Range
Age at ascertainment, y	3,453	50	18–91	3,051	51	18–101
Time to PCa or censoring, y	3,453	50	18–91	3,051	54	18–101
Age at PCa diagnosis, y	65	64	30–85	171	64	29–87
Age at other cancer diagnosis, y	332	59	19–88	657	60	21–88

Abbreviation: PCa, prostate cancer.

CI, 1.34–2.66; $P = 3 \times 10^{-4}$, respectively). Similarly, we repeated the analysis including only self-identified Caucasians. In part, because of the small number of non-Caucasians in the study, the point estimates did not change to the second decimal place compared with the total sample that included non-Caucasians. Finally, we corrected for correlation due to the presence of multiple individuals in a family. With and without this correction, no change in the inferences was observed.

PSV type and function

In addition to seeking for regional variation in prostate cancer risk associated with PSVs across *BRCA1/2*, we also evaluated potential genotype–phenotype correlations by PSV type or function (Table 3). No PSV groups defined by type or function were significantly associated with prostate cancer for either *BRCA1* or *BRCA2*.

Discussion

Using a multinational data resource of approximately 6,500 men carrying a *BRCA1/2* PSV, we identified two regions in *BRCA2* (c.756-c.1000 and c.7914+) that were associated with increased risk of prostate cancer diagnosis and of Gleason 8+ prostate cancer. These data suggest that PSV-specific PCA risks exist for *BRCA2* PSV carriers.

This observation is consistent with earlier studies reporting a PSV-specific increase in prostate cancer risk among *BRCA1/2* PSV carriers (31, 32). However, most studies that have made these observations have estimated the prevalence of *BRCA1/2* mutations in prostate cancer cases. Few studies have evaluated prostate cancer incidence in mutation *BRCA1/2* carriers. Nielsen and colleagues (32) reported an elevated prostate cancer relative risk in *BRCA2* mutation carriers whose mutations fell in c.6373-c.6492 with a relative risk of 3.7 for mutations within this region compared with mutations outside this region. This elevated relative risk was not observed in the larger current analysis, which included the carriers reported by Nielsen and colleagues. We also demonstrated a remarkable similarity between PSVs conferring increased prostate cancer risk and those associated with increased breast cancer risk in female *BRCA2* PSV carriers (24).

BRCA2 is among the few known clinically relevant loci, in which many deleterious variants cause a highly penetrant prostate cancer predisposition (50). Our work addressed the hypothesis that germline PSVs in *BRCA1/2* that influence development of overall prostate cancer and prostate cancer severity demonstrate nonrandom distribution by location and/or function of the gene. Because patients with prostate cancer with Gleason 8+ disease are far more likely than men with Gleason <8 prostate cancer to have unfavorable clinical outcome (2, 11–18), the observation that PCCR PSVs are associated

Table 3. Association of PSV type or function with risk of prostate cancer.

PSV type	N	PCa	BRCA1 mutation carriers		BRCA2 mutation carriers			
			HR (95% CI)	P	N	PCa	HR (95% CI)	P
Premature truncating codon	2,720	54 (2.0%)	1.04 (0.47–2.28)	0.931	2,699	151 (5.6%)	0.90 (0.40–2.04)	0.805
Nonsense-mediated decay	1,996	31 (1.6%)	0.65 (0.38–1.11)	0.117	2,692	150 (5.6%)	0.86 (0.41–1.82)	0.698
Class 1	2,489	48 (1.9%)	0.80 (0.44–1.47)	0.474	2,712	151 (5.6%)	0.81 (0.37–1.78)	0.596
Deletion	279	5 (1.8%)	0.79 (0.32–1.95)	0.606	57	5 (8.8)	1.25 (0.51–3.08)	0.469
Frameshift	1,845	43 (2.3%)	1.66 (0.99–2.77)	0.055	2,040	115 (5.6%)	1.01 (0.74–1.41)	0.910
Insertion	61	0	— ^a	— ^a	21	0	— ^a	— ^a
Missense	283	3 (1.1%)	0.66 (0.21–2.11)	0.488	60	4 (7%)	1.08 (0.37–3.17)	0.886
Nonsense	679	9 (1.3%)	0.68 (0.34–1.36)	0.271	591	32 (5.4%)	0.94 (0.64–1.39)	0.740
Splicing	306	5 (1.6%)	0.94 (0.39–2.30)	0.896	282	15 (5.3%)	1.00 (0.57–1.76)	0.994

Note: HRs represent the comparison of PSVs with a certain type or function designation vs. all other PSVs. HRs are adjusted for year of birth cohort, race, and country of ascertainment.

Abbreviation: PCa, prostate cancer.

^aCould not be estimated.

with elevated Gleason score suggests that PCCR PSVs may be associated with poorer prognosis than other *BRCA2* PSVs. However, this needs to be investigated in future studies. We observe an elevated risk of both Gleason 8+ and Gleason ≤ 7 cancers, although the magnitude of association for Gleason 8+ is higher than that for Gleason ≤ 7 . Thus, it is possible that the PCCR reported here is associated with prostate cancer in general, and not only with high-grade prostate cancer. This observation requires additional research to confirm. In addition, knowledge of the importance of DNA damage repair suggests that the mechanism of prostate carcinogenesis is broadly modified by *BRCA2*-related pathways (23). The IMPACT trial reported that PSA screening may be more informative in detecting prostate cancer in *BRCA2* PSV carriers compared with noncarriers (51). Additional research is needed to evaluate whether the PCCR PSVs reported here also influence the results of different management strategies.

In addition to its colocation with a previously identified breast cancer cluster region (24), PSVs in the PCCR (3' of c.7914) are focused within two of the principal DNA-binding domains of the OB1 (i.e., oligonucleotide/oligosaccharide-binding domain 1; amino acids 2670–2796) and OB2 (i.e., Tower ssDNA and dsDNA binding domain 2; amino acids 2831–2872). However, the current dataset does not allow us to understand the mechanism that might explain why *BRCA2* PCCR PSVs are associated with elevated prostate cancer risks. Additional mechanistic research will be required to elucidate the biological basis for risk heterogeneity implied by the present results.

The most common PSV in the c.756–c.1000 region was the Icelandic and Finnish founder PSV, c.771_775del, which has long been known as a prostate cancer predisposition PSV (52–54) and is associated with a rapid progression to fatal prostate cancer (10). Thus, our results regarding the association of this founder PSV with prostate cancer severity are consistent with this prior report. We were not able to infer if c.756–c.1000 is a second PCCR region, or if the observed effect is due solely to c.771_775del. We returned to the original data from participants with this PSV to identify any potential bias in ascertainment that may have influenced this result. On the basis of original records from the Icelandic clinics from which these men were ascertained, no individual was ascertained based on genetic testing of prostate cancer. The carriers of this PSV were identified through family studies of breast cancer, mainly by screening unselected patients with breast cancer and then, if mutation positive, by screening their close relatives. There was no ascertainment preference for prostate cancer in Icelandic male carriers and there was no instance of a

BRCA2 carrier identified by testing prostate cancer cases (Aðalgeir Arason; personal communication).

Our current results complement the growing body of knowledge that cancer-susceptible PSVs demonstrate clinically relevant genotype–phenotype relationships. PSV location within *APC* is associated with polyposis severity and prevalence of extracolonic features, such as desmoid fibromas (55). Similarly, genotype–phenotype relationships have been reported for (missense) PSVs in *RET* in multiple endocrine neoplasia type 2 (MEN2) and familial medullary thyroid carcinoma (30). These findings have shaped the Neuroendocrine Tumor Society consensus guidelines, which now suggest thyroidectomy before age 5 years for individuals with PSVs within these high-risk regions, providing insight into the structure and function of cancer susceptibility PSVs in these genes and guiding clinical risk assessment and management. Despite evidence of genotype–phenotype relationships at multiple loci, the characteristics and mechanistic influences on cancer risk are likely quite different for PSVs in *APC*, *RET*, *BRCA1/2*, and others.

In contrast to prior work that evaluated prevalence of PSVs in *BRCA1/2* in various prostate cancer case series, we have leveraged a large, international multicenter consortium study of *BRCA1/2* PSV carriers, irrespective of prostate cancer status. However, our analysis has some limitations. The CIMBA study uses a nonstandardized recruitment strategy from multiple referral centers. Thus, our data may not represent either the full spectrum of patients with prostate cancer or *BRCA1/2* PSV carriers in the general population. Similarly, we were not able to assess issues of survival bias in our data that may be related to cancer screening or treatment.

While this study identifies potentially interesting PSV-specific prostate cancer associations, there are limitations in the data and analysis that require future validation. We used two binning approaches to identify relevant regions of *BRCA1/2* that could have different risk or penetrance effects on prostate cancer based on our earlier research that undertook a similar analysis for breast and ovarian cancer (24). In that analysis, we determined that the combination of these two approaches were complementary and identified similar regions of interest. While this approach points toward genomic regions that may confer different prostate cancer risks, a full understanding of the causes of the effects we report will require experimental and mechanistic studies to further define the boundaries of the relevant domains and to understand the underlying mechanisms that lead to the observations reported here. In addition, the choice of the reference bin in our analysis will affect estimates of the HRs reported here. Thus,

this report focuses on the identification of genomic regions that may confer elevated prostate cancer risks in *BRCA2* mutation carriers, and the HR estimates presented here should be interpreted with caution and not used for clinical risk estimation purposes.

Studies in female PSV carriers using a study design similar to that used here applied analytic corrections to account for the possibility that affected individuals (particularly those affected at younger ages) are more likely to be sampled than unaffected individuals. Unlike prior breast and ovarian cancer studies in *BRCA1/2* mutation carriers, this sample did not ascertain specific prostate cancer cases (e.g., those diagnosed at an early age). Our median age at diagnosis is 64 years, which is similar to that reported in other non-*BRCA1/2* populations. Our case sample is substantially older than prostate cancer cases ascertained for *BRCA1/2* screening studies, which tend to have a large proportion of cases diagnosed before the age of 55 years (56). Thus, while there is limited evidence that ascertainment of cases conferred a major bias to the present results, future research is required to determine the extent of bias in our relative risk estimates arising from these issues.

Finally, pathology review of prostate tumors was neither centralized nor available for all cases. A relatively large proportion of Gleason score and tumor stage data were also missing from the present sample, because many cases were based on self-report only. Cases with missing tumor stage and grade were excluded from those analyses, so any differential reporting of tumor traits could have caused bias in those results.

This study indicates that personalized prostate cancer risk assessment may be a future option, as well as individualized clinical management based on the specific *BRCA2* PSV status. Additional research is required to fully understand the implication of carrying specific *BRCA2* PSVs. Further characterization of the relationship between these PSVs and various cancer outcomes might help direct the future use of DNA repair-directed treatments and radiotherapy in men carrying these PSVs.

Disclosure of Potential Conflicts of Interest

A. Borg has received speakers bureau honoraria from Roche and AstraZeneca (lecture honoraria). A.R. Bradbury has received other commercial research support and is a consultant/advisory board member for AstraZeneca and Merck. N. Ditsch has received speakers bureau honoraria from MSD, Roche, TEVA and has provided expert testimony as a mentor. D.M. Eccles has received speakers bureau honoraria from AstraZeneca and Pierre Fabre. R.A. Eeles has received speakers bureau honoraria from GU-ASCO meeting in San Francisco (January 2016; honorarium as speaker), from RMH FR meeting (November 2017; support from Janssen, honorarium as speaker; title: Genetics and Prostate Cancer), University of Chicago (invited talk May 2018; honorarium as speaker). D.G. Evans is a consultant/advisory member for AstraZeneca. G. Fountzilas has received speakers bureau honoraria from AstraZeneca. O.I. Olopade reports receiving other commercial research support from CancerIQ. M.A. Pujana has received other commercial research support from Roche Pharma. M.E. Robson has received other commercial research support from Invitae and Myriad and is a consultant/advisory board member for AstraZeneca, Merck, Pfizer, Daiichi Sankyo, McKesson. K.J. Ruddy has ownership interest (including patents) in Merck and Pfizer. L. Senter is a consultant/advisory board member for AstraZeneca and Clovis and has received speakers bureau honoraria from AstraZeneca. C.F. Singer is a consultant at Novartis, has received speakers bureau honoraria from Roche, Novartis, Amgen, and is a consultant/advisory board member for AstraZeneca. L. Varesco is on expert input forum at AstraZeneca-MSD. No potential conflicts of interest were disclosed by the other authors.

Disclaimer

The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. The content is

solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Authors' Contributions

Conception and design: V.L. Patel, E.L. Busch, D.F. Easton, K.-P. Ko, C. Lazaro, M.H. Lee, A. Lindblom, G. Chenevix-Trench, L. Ottini, H.R. Nielsen, T.R. Rebbeck
Development of methodology: V.L. Patel, E.L. Busch, D.F. Easton, M.H. Lee, D. Torres, S. Wang-Gohrke, H.R. Nielsen, T.R. Rebbeck

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): G. Leslie, J. Adlard, S. Agata, B.A. Agnarsson, M. Ahmed, E. Alducci, K. Aittomäki, I.L. Andrulis, A. Arason, N. Arnold, G. Artioli, B. Arver, B. Auber, J. Azzollini, R.B. Barkardottir, A. Barroso, D. Barrowdale, M. Belotti, J. Benitez, M.J. Blok, V. Bonadona, B. Bonanni, D. Bondavalli, S.E. Boonen, J. Borde, A. Borg, A.R. Bradbury, A. Brady, C. Brewer, J. Brunet, B. Buecher, S.S. Buys, S. Cabezas-Camarero, A. Caliebe, M.A. Caligo, M. Calvello, I.G. Campbell, E. Carrasco, T.L. Chan, A.T.W. Chu, W.K. Chung, K.B.M. Claes, GEMO Study Collaborators, J. Cook, L. Cortesi, F.J. Couch, M.B. Daly, G. Damante, E. Darder, R. Davidson, M. de la Hoya, O. Díez, Y.C. Ding, N. Ditsch, S.M. Domchek, A. Donaldson, B. Dworniczak, D.F. Easton, D.M. Eccles, H. Ehrencrona, B. Ejertsen, D.G. Evans, L. Faivre, U. Faust, L. Feliubadaló, L. Foretova, F. Fostira, G. Fountzilas, D. Frost, V. García-Barberán, P. Garre, M. Gauthier-Villars, L. Géczi, A. Gehrig, A.-M. Gerdes, P. Gesta, G. Giannini, G. Glendon, A.K. Godwin, M.H. Greene, M.H. Greene, A.M. Gutierrez-Barrera, E. Hahnen, U. Hamann, J. Hauke, N. Herold, F.B.L. Hogervorst, E. Honisch, J.L. Hopper, P.J. Hulick, KConFab Investigators, HEBOIN Investigators, L. Izatt, P. James, R. Janavicius, U.B. Jensen, O.T. Johannsson, E.M. John, V. Joseph, E. Kang, K. Kast, J.I. Kiiski, S.-W. Kim, I. Konstantopoulou, G. Kramer, L. Krogh, T.A. Kruse, A. Kwong, M. Larsen, C. Lasset, C. Lazaro, J. Lee, J.W. Lee, M.H. Lee, J. Lemke, F. Lesueur, A. Lindblom, A. Lopez-Fernández, I. Lopez-Perolio, V. Lorca, J.T. Loud, E.S.K. Ma, P.L. Mai, S. Manoukian, V. Mari, L. Martin, L. Matricardi, N. Mebirouk, V. Medici, H.E.J. Meijers-Heijboer, A. Meindl, A.R. Mensenkamp, D. Molina Gomes, M. Montagna, T.M. Mooij, L. Moserle, E. Mouret-Fourme, A.M. Mulligan, K.L. Nathanson, M. Navratilova, H. Nevanlinna, D. Niederacher, F.C. Cilius Nielsen, L. Nikitina-Zake, K. Offit, E. Olah, O.I. Olopade, K.-R. Ong, A. Osorio, C.-E. Ott, D. Palli, S.K. Park, M.T. Parsons, I.S. Pedersen, B. Peissel, A. Peixoto, P. Pérez-Segura, P. Peterlongo, M.E. Porteous, M.A. Pujana, L.D. Pappa, P. Radice, J. Ramser, J. Rantala, M.U. Rashid, K. Rhiem, P. Rizzolo, M.E. Robson, M.A. Rookus, C.M. Rossing, C. Santos, C. Saule, R. Scarpitta, R.K. Schmutzler, H. Schuster, L. Senter, C.M. Seynaeve, P.D. Shah, P. Sharma, V. Silvestri, J. Simard, C.F. Singer, A.R. Solano, P. Soucy, M.C. Southey, A.B. Spurdle, L. Steele, D. Steinemann, D. Stoppa-Lyonnet, A. Stradella, L. Sunde, Y.Y. Tan, M.R. Teixeira, S.H. Teo, M.G. Tibiletti, M. Tischkowitz, S. Tognazzo, A.E. Toland, S. Tommasi, D. Torres, A. Toss, C.J. van Asperen, L.E. van der Kolk, L.P. van Hest, L. Varesco, A. Viel, J. Vierstraete, R. Villa, A. von Wachenfeldt, P. Wagner, S. Wang-Gohrke, B. Wappenschmidt, J.N. Weitzel, G. Wieme, S. Yadav, D. Yannoukakos, S.-Y. Yoon, K.K. Zorn, M.M. Pomerantz, G. Chenevix-Trench, A.C. Antoniou, S.L. Neuhausen, H.R. Nielsen, T.R. Rebbeck

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): V.L. Patel, A. Cronin, B. Auber, D.R. Barnes, B. Bertelsen, T.L. Chan, M. de la Hoya, D.G. Evans, L. Feliubadaló, F. Fostira, M.H. Greene, M.H. Greene, E. Hahnen, KConFab Investigators, O.T. Johannsson, V. Joseph, K.-P. Ko, I. Konstantopoulou, C. Lazaro, M.H. Lee, A. Liljegren, P. Llovet, A. Meindl, K. Rhiem, V.Y. Shin, M.C. Southey, A.B. Spurdle, A. Stradella, L. Sunde, M. Thomassen, N. Tung, P. Wagner, A.V. D'Amico, H.R. Nielsen, T.R. Rebbeck

Writing, review, and/or revision of the manuscript: V.L. Patel, E.L. Busch, T.M. Friebe, A. Cronin, J. Adlard, B.A. Agnarsson, K. Aittomäki, I.L. Andrulis, A. Arason, N. Arnold, B. Auber, J. Azzollini, R.B. Barkardottir, A. Barroso, D. Barrowdale, J. Benitez, B. Bertelsen, M.J. Blok, V. Bonadona, D. Bondavalli, S.E. Boonen, A. Borg, A.R. Bradbury, B. Buecher, S.S. Buys, M. Calvello, A.T.W. Chu, W.K. Chung, K.B.M. Claes, F.J. Couch, M.B. Daly, M. de la Hoya, O. Díez, N. Ditsch, S.M. Domchek, D.F. Easton, D.M. Eccles, R.A. Eeles, H. Ehrencrona, B. Ejertsen, D.G. Evans, L. Faivre, L. Feliubadaló, F. Fostira, D. Frost, V. García-Barberán, P. Garre, L. Géczi, A.-M. Gerdes, G. Giannini, G. Glendon, A.K. Godwin, D.E. Goldgar, M.H. Greene, M.H. Greene, U. Hamann, J.L. Hopper, P.J. Hulick, KConFab Investigators, L. Izatt, A. Jager, P. James, R. Janavicius, U.B. Jensen, O.T. Johannsson, E.M. John, V. Joseph, S.-W. Kim, I. Konstantopoulou, T.A. Kruse, A. Kwong, C. Lazaro, M.H. Lee, A. Lindblom, J.T. Loud, P.L. Mai, S. Manoukian, H.E.J. Meijers-Heijboer, A.R. Mensenkamp, E. Mouret-Fourme, K.L. Nathanson, K. Offit, E. Olah, A. Osorio, D. Palli, I.S. Pedersen, P. Pérez-Segura, P. Peterlongo, A.H. Petersen, P. Radice, M.U. Rashid, K. Rhiem, P. Rizzolo, M.E. Robson, K.J. Ruddy,

R.K. Schmutzler, L. Senter, C.M. Seynaeve, V. Silvestri, C.F. Singer, A.R. Solano, L. Steele, D. Steinemann, D. Stoppa-Lyonnet, A. Stradella, L. Sunde, Y.Y. Tan, S.H. Teo, M. Thomassen, M. Tischkowitz, A.E. Toland, N. Tung, L.E. van der Kolk, L.P. van Hest, L. Varesco, R. Villa, J.N. Weitzel, S. Yadav, D. Yannoukakos, A.V. D'Amico, M.L. Freedman, M.M. Pomerantz, G. Chenevix-Trench, A.C. Antoniou, S.L. Neuhausen, L. Ottini, H.R. Nielsen, T.R. Rebbeck

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. McGuffog, D. Barrowdale, M.J. Blok, GEMO Study Collaborators, M. de la Hoya, J. Dennis, D.M. Eccles, L. Foretova, A.M. Gutierrez-Barrera, J. Hauke, F.B.L. Hogervorst, KConFab Investigators, P. James, T.D. Jensen, C. Lautrup, J. Lemke, F. Lesueur, A. Liljegen, J.T. Loud, E.S.K. Ma, K.L. Nathanson, K. Offit, M.T. Parsons, B. Peissel, K. Rhiem, P. Sharma, C.F. Singer, A.R. Solano, M.C. Southey, A.B. Spurdle, L. Steele, C. Sutter, D. Torres, R.B. van der Luijt, P. Wagner, S. Wang-Gohrke, J.N. Weitzel, A.V. D'Amico, G. Chenevix-Trench, A.C. Antoniou, H.R. Nielsen, T.R. Rebbeck

Study supervision: L. Géczi, J.T. Loud, C. Miller, K. Offit, S.K. Park, C.F. Singer, M.C. Southey, A.B. Spurdle, A.C. Antoniou, H.R. Nielsen, T.R. Rebbeck

Acknowledgments

The authors thank all the families and clinicians who contributed to the studies; Sue Healey, in particular taking on the task of PSV classification with the late Olga Sinilnikova; Maggie Angelakos, Judi Maskiell, Gillian Dite, Helen Tsimiklis; members and participants in the New York site of the Breast Cancer Family Registry; members and participants in the Ontario Familial Breast Cancer Registry; Vilnius Rudaitis and Laimonas Gris?kevicius; Drs. Janis Eglitis, Anna Krilova, and Aivars Stengrevics; Rosario Alonso and Guillermo Pita; Milena Mariani, Daniela Zaffaroni, Monica Barile, Irene Feroce, Riccardo Dolcetti, Laura Papi, Gabriele Lorenzo Capone, Viviana Gismondi, Daniela Furlan, Antonella Savarese, Aline Martayan, Brunella Pilato; the personnel of the Cogentech Cancer Genetic Test Laboratory, Milan, Italy. Ms. JoEllen Weaver and Dr. Betsy Bove; Marta Santamarina, Ana Blanco, Miguel Aguado, Uxia Esperón, and Belinda Rodríguez; IFE - Leipzig Research Centre for Civilization Diseases (Markus Loeffler, Joachim Thiery, Matthias Nüchter, Ronny Baber). We also thank all participants, clinicians, family doctors, researchers, and technicians for their contributions and commitment to the DKFZ study and the collaborating groups in Lahore, Pakistan (Muhammad U. Rashid, Noor Muhammad, Sidra Gull, Seerat Bajwa, Faiz Ali Khan, Humaira Naemi, Saima Faisal, Asif Loya, Mohammed Asim Yusuf) and Bogota, Colombia (Ignacio Briceno, Fabian Gil). Genetic modifiers of cancer risk in BRCA1/2 mutation carriers (GEMO) study is a study from the National Cancer Genetics Network UNICANCER Genetic Group, France. We wish to pay a tribute to Olga M. Sinilnikova, who initiated and coordinated GEMO until she sadly passed away on the 30th June 2014. The team in Lyon (Olga M. Sinilnikova, Mélanie Léone, Laure Barjhoux, Carole Verny-Pierre, Sylvie Mazoyer, Francesca Damiola, Valérie Sornin) managed the GEMO samples until the biological resource center was transferred to Paris in December 2015. We want to thank all the GEMO collaborating groups for their contribution to this study: Coordinating Centre, Service de Génétique, Institut Curie, Paris, France: Ophélie Bertrand, Anne-Marie Birot, Sandrine Caputo, Anaïs Dupré, Emmanuelle Fourme, Lisa Golmard, Claude Houdayer, Marine Le Mentec, Virginie Moncoutier, Antoine de Pauw, Dominique Yen, and Inserm U900, Institut Curie, Paris, France: Fabienne Lesueur, Noura Mebirouk. Contributing centers: Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon - Centre Léon Bérnard, Lyon, France: Nadia Boutry-Kryza, Alain Calender, Sophie Giraud, Mélanie Léone. Institut Gustave Roussy, Villejuif, France: Birgitte Bressac-de-Paillerets, Olivier Caron, Marine Guillaud-Bataille. Centre Jean Perrin, Clermont-Ferrand, France: Yves-Jean Bignon, Nancy Uhrhammer. Centre François Baclesse, Caen, France: Pascaline Berthet, Laurent Castera, Dominique Vaur. Institut Paoli Calmettes, Marseille, France: Violaine Bourdon, Catherine Nogués, Tetsuro Noguchi, Cornel Popovici, Audrey Remenieras, Hagay Sobol. CHU Arnaud-de-Ville-neuve, Montpellier, France: Isabelle Coupier, Pascal Pujol. Centre Oscar Lambret, Lille, France: Claude Adenis, Aurélie Dumont, Françoise Révillon. Centre Paul Strauss, Strasbourg, France: Danièle Muller. Institut Bergonié, Bordeaux, France: Emmanuelle Barouk-Simonet, Françoise Bonnet, Virginie Bubié, Michel Longy, Nicolas Sevenet, Institut Claudius Regaud, Toulouse, France: Laurence Gladieff, Rosine Guimbaud, Viviane Feillel, Christine Toulas. CHU Grenoble, France: Hélène Dreyfus, Christine Dominique Leroux, Magalie Peysselon, Rebschung. CHU Dijon, France: Amandine Baurand, Geoffrey Bertolone, Fanny Coron, Caroline Jacquot, Sarab Lizard. CHU St-Etienne, France: Caroline Kientz, Marine Lebrun, Fabienne Prieur. Hôtel Dieu Centre Hospitalier, Chambéry, France: Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice, France: Véronique Mari.

CHU Limoges, France: Laurence Vénat-Bouvet. CHU Nantes, France: Stéphane Bézieau, Capucine Delnatte. CHU Bretonneau, Tours, and Centre Hospitalier de Bourges France: Isabelle Mortemousque. Groupe Hospitalier Pitié-Salpêtrière, Paris, France: Chrystelle Colas, Florence Coulet, Florent Soubrier, Mathilde Warcoin. CHU Vandoeuvre-les-Nancy, France: Myriam Bronner, Johanna Sokolowska. CHU Besançon, France: Marie-Agnès Collonge-Rame, Alexandre Damette. CHU Poitiers, Centre Hospitalier d'Angoulême, and Centre Hospitalier de Niort, France: Hakima Lallaoui. CHU Nîmes Carémeau, France: Jean Chiesa. CHI Poissy, France: Denise Molina-Gomes. CHU Angers, France: Olivier Ingster; Ilse Coene en Brecht Crombez; Ilse Coene and Brecht Crombez; Alicia Tosar and Paula Diaque; Sofia Khan, Taru A. Muranen, Carl Blomqvist, Irja Erkkilä, and Virpi Palola; The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) consists of the following Collaborating Centers: Coordinating center: Netherlands Cancer Institute, Amsterdam, NL: F.E. van Leeuwen, S. Verhoef, M.K. Schmidt, N. S. Russell, D.J. Jenner; Erasmus Medical Center, Rotterdam, NL: J.M. Collé, A.M. W. van den Ouweland, M.J. Hooning, C.H.M. van Deurzen, I.M. Obdeijn; Leiden University Medical Center, NL: J.T. Wijnen, R.A.E.M. Tollenaar, P. Devilee, T.C.T. E.F. van Cronenburg; Radboud University Nijmegen Medical Center, NL: C.M. Kets; University Medical Center Utrecht, NL: M.G.E.M. Ausems, C.C. van der Pol; Amsterdam Medical Center, NL: C.M. Aalfs, T.A.M. van Os; VU University Medical Center, Amsterdam, NL: J.J.P. Gille, Q. Waisfisz; University Medical Center Groningen, NL: J.C. Oosterwijk, A.H. van der Hout, M.J. Mourits, G.H. de Bock; The Netherlands Foundation for the detection of hereditary tumors, Leiden, NL: H.F. Vasen; The Netherlands Comprehensive Cancer Organization (IKNL): S. Siesling, J.Verloop; The Dutch Pathology Registry (PALGA): L.L.H. Overbeek; Hong Kong Sanatorium and Hospital; the Hungarian Breast and Ovarian Cancer Study Group members (Janos Papp, Aniko Bozsik, Tímea Poczva, Zoltan Matrai, Miklos Kasler, Judit Franko, Maria Balogh, Gabriella Domokos, Judit Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary), and the clinicians and patients for their contributions to this study; the Oncogenetics Group (VHIO) and the High Risk and Cancer Prevention Unit of the University Hospital Vall d'Hebron, and the Cellex Foundation for providing research facilities and equipment; the ICO Hereditary Cancer Program team led by Dr. Gabriel Capella; the ICO Hereditary Cancer Program team led by Dr. Gabriel Capella; Dr Martine Dumont for sample management and skillful assistance; Pedro Pinto; members of the Center of Molecular Diagnosis, Oncogenetics Department and Molecular Oncology Research Center of Barretos Cancer Hospital; Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (which has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the NIH) for their contributions to this resource, and the many families who contribute to kConFab; the KOBRA Study Group; Csilla Szabo (National Human Genome Research Institute, NIH, Bethesda, MD), Eva Machackova (Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic); and Michal Zikan, Petr Pohreich, and Zdenek Kleibl (Oncogynecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic); Anne Lincoln, Lauren Jacobs; the NICCC National Familial Cancer Consultation Service team led by Sara Dishon, the lab team led by Dr. Flavio Lejbkovicz, and the research field operations team led by Dr. Mila Pinchev; the investigators of the Australia New Zealand NRG Oncology group; members and participants in the Ontario Cancer Genetics Network; Kevin Sweet, Caroline Craven, Julia Cooper, and Michelle O'Connor; Yip Cheng Har, Nur Aishah Mohd Taib, Phuah Sze Yee, Norhashimah Hassan, and all the research nurses, research assistants, and doctors involved in the MyBrCa Study for assistance in patient recruitment, data collection, and sample preparation, Philip Iau, Sng Jen-Hwei, and Sharifah Nor Akmal for contributing samples from the Singapore Breast Cancer Study and the HUKM-HKL Study, respectively; the Meirav Comprehensive breast cancer center team at the Sheba Medical Center; Christina Selkirk; Håkan Olsson, Helena Jernström, Karin Henriksson, Katja Harbst, Maria Soller, Ulf Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Anna Öfverholm, Margareta Nordling, Per Karlsson, Zakaria Einbeigi; from Stockholm and Karolinska University Hospital: Gisela Barbany Bustinza; from Umeå University Hospital: Beatrice Melin, Christina Edwinsdotter Ardnor, Monica Emanuelsson; from Uppsala University: Maritta Hellström Pigg, Richard Rosenquist; from Linköping University Hospital: Marie Stenmark-Askmaln, Sigrun Liedgren; Cecilia Zwocec, Qun Niu; Joyce Seldon and Lorna Kwan; Dr. Robert Nussbaum, Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Blanco, and Peggy Conrad and Salina Chan; Simon Gayther, Susan Ramus, Paul Pharoah, Carole Pye, Patricia Harrington, and Eva Wozniak; Geoffrey

Lindeman, Marion Harris, Martin Delatycki, Sarah Sawyer, Rebecca Driessen, and Ella Thompson for performing all DNA amplification. E.L. Busch was supported by grants from the National Cancer Institute (5T32CA009001, P60-CA105641). The CIMBA data management and data analysis were supported by Cancer Research – UK grants C12292/A20861, C12292/A11174. A.C. Antoniou is a Cancer Research-UK Senior Cancer Research Fellow. G. Chenevix-Trench and A.B. Spurdle are NHMRC Research Fellows. iCOGS: the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the NIH (CA128978), and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065, and 1U19 CA148112 - the GAME-ON initiative), the Department of Defense (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer (CRN-87521), and the Ministry of Economic Development, Innovation and Export Trade (PSR-SIIRI-701), Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The PERSPECTIVE project was supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministry of Economy, Science and Innovation through Genome Québec, and The Quebec Breast Cancer Foundation. BCFR: UM1 CA164920 from the National Cancer Institute. BFBOCC: Lithuania (BFBOCC-LT): Research Council of Lithuania grant SEN-18/2015. BIDMC: Breast Cancer Research Foundation. MBMSA: Cancer Association of South Africa (principal investigator: Elizabeth J. van Rensburg). CNIO: Spanish Ministry of Health PI16/00440 supported by FEDER funds, the Spanish Ministry of Economy and Competitiveness (MINECO) SAF2014-57680-R and the Spanish Research Network on Rare diseases (CIBERER). COH-CCGCRN: Research reported in this publication was supported by the NCI of the NIH under grant numbers R25CA112486 and RC4CA153828 (principal investigator: J. Weitzel) from the NCI and the Office of the Director, NIH. CONSIT: Associazione Italiana Ricerca sul Cancro (AIRC; IG2014 no.15547 to P. Radice). Italian Association for Cancer Research (AIRC; grant no.16933 to L. Ottini). Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732 to P. Peterlongo). Associazione Italiana Ricerca sul Cancro (AIRC grant IG17734 to G. Giannini). DEMOKRITOS: European Union (European Social Fund – ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program of the General Secretariat for Research & Technology: SYN11_10_19 NBCA. Investing in knowledge society through the European Social Fund. DFKZ: German Cancer Research Center. EMBRACE: Cancer Research UK Grants C1287/A10118 and C1287/A11990. Fiona Laloo is supported by an NIHR grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Elizabeth Bancroft is supported by Cancer Research UK Grant C5047/A8385FCCC: The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program. A.K. Godwin was funded by R01CA140323, R01 CA214545, and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship. FPGMX: FISPI05/2275 and Mutua Madrileña Foundation (FMMA). GC-HBOC: German Cancer Aid (grant no 110837 to R.K. Schmutzler) and the European Regional Development Fund and Free State of Saxony, Germany (LIFE - Leipzig Research Centre for Civilization Diseases, project numbers 713-241202, 713-241202, 14505/2470, 14575/2470). GEMO: Ligue Nationale Contre le Cancer; the Association "Le cancer du sein, parlons-en!" Award, the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program and the French National Institute of Cancer (INCa). GEORGETOWN: the Non-Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI grant P30-CA051008), the Fisher Center for Hereditary Cancer and Clinical Genomics Research, and Swing Fore the Cure. G-FAST: Bruce Poppe is a senior clinical investigator of FWO. Mattias Van Heetvelde obtained funding from IWT. HCSC: Spanish Ministry of Health PI15/00059, PI16/01292, and CB-161200301 CIBERONC from ISCIII (Spain), partially supported by European Regional Development FEDER funds. HEBCS: Helsinki University Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and the Sigrid Juselius Foundation. HEBON: the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant

NWO 184.021.007/CP46, and the Transcan grant JTC 2012 Cancer 12-054. HEBON thanks the registration teams of Dutch Cancer Registry (IKNL; S. Siesling, J. Verloop) and the Dutch Pathology database (PALGA; L. Overbeek) for part of the data collection. HRBCP: Hong Kong Sanatorium and Hospital, Dr Ellen Li Charitable Foundation, The Kerry Group Kuok Foundation, NIH1R 03CA130065, and North California Cancer Center. HUNBOCS: Hungarian Research Grants KTIA-OTKA CK-80745 and OTKA K-112228. ICO: The authors would like to particularly acknowledge the support of the Asociación Española Contra el Cáncer (AECC), the Instituto de Salud Carlos III (organismo adscrito al Ministerio de Economía y Competitividad) and "Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa" (PI10/01422, PI13/00285, PIE13/00022, PI15/00854, PI16/00563 and CIBERONC), and the Institut Català de la Salut and Autonomous Government of Catalonia (2009SGR290, 2014SGR338, and PERIS Project MedPerCan). IHCC: PBZ_KBN_122/P05/2004. ILUH: Icelandic Association "Walking for Breast Cancer Research" and by the Landspítali University Hospital Research Fund. INHERIT: Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program – grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade – grant # PSR-SIIRI-701. IOVHBOCS: Ministero della Salute and "5 × 1000" Istituto Oncologico Veneto grant. IPOBCS: Liga Portuguesa Contra o Cancro. kConFab: The National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. MAYO: NIH grants CA116167, CA192393, and CA176785, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), and a grant from the Breast Cancer Research Foundation. MCGILL: Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation and Export Trade. MSKCC: the Breast Cancer Research Foundation, the Robert and Kate Niehaus Clinical Cancer Genetics Initiative, the Andrew Sabin Research Fund and a Cancer Center Support Grant/Core Grant (P30 CA008748). NAROD: 1R01 CA149429-01. NCI: the Intramural Research Program of the NCI, NIH, and by support services contracts NO2-CP-11019-50, N02-CP-21013-63 and N02-CP-65504 with Westat, Inc, Rockville, MD. NICCC: Clalit Health Services in Israel, the Israel Cancer Association and the Breast Cancer Research Foundation (BCRF), NY. NNPIO: The Russian Federation for Basic Research (grants 15-04-01744, 16-54-00055, and 17-54-12007). NRG Oncology: U10 CA180868, NRG SDMC grant U10 CA180822, NRG Administrative Office and the NRG Tissue Bank (CA 27469), the NRG Statistical and Data Center (CA 37517) and the Intramural Research Program, NCI. OSUCCG: Ohio State University Comprehensive Cancer Center. PBCS: Italian Association of Cancer Research (AIRC) [IG 2013 N.14477] and Tuscan Institute for Tumors (ITT) grant 2014-2015-2016. SEABASS: Ministry of Science, Technology and Innovation, Ministry of Higher Education (UM. C/HIR/MOHE/06) and Cancer Research Initiatives Foundation. SMC: the Israeli Cancer Association. SWE-BRCA: the Swedish Cancer Society. UCHICAGO: NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, 1U01CA161032, and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women's Cancer Research Alliance, and the Breast Cancer research Foundation. O.I. Olopade is an ACS Clinical Research Professor. UCLA: Jonsson Comprehensive Cancer Center Foundation; Breast Cancer Research Foundation. UCSF: UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center. UKFOCR: Cancer Research UK. UPENN: Breast Cancer Research Foundation; Susan G. Komen Foundation for the Cure, Basser Center for BRCA. UPITT/MWH: Hackers for Hope Pittsburgh. VFCTG: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation. WCP: Dr Karlan is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS; grant no. UL1TR000124). S. Gutiérrez-Enriquez is supported by the Miguel Servet Program (CP10/00617).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 1, 2019; revised August 7, 2019; accepted November 8, 2019; published first November 13, 2019.

References

- Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. *J Med Genet* 2003;40:787–92.
- Gallagher DJ, Gaudet MM, Pal P, Kirchoff T, Balistreri L, Vora K, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. *Clin Cancer Res* 2010;16:2115–21.
- Kirchoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. *Clin Cancer Res* 2004;10:2918–21.
- Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, Stanford JL. Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. *Cancer Causes Control* 2010;21:289–300.
- Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. *Clin Cancer Res* 2009;15:1112–20.
- Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA, et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. *Br J Cancer* 2007;97:826–31.
- Agalliu I, Kwon EM, Zadory D, McIntosh L, Thompson J, Stanford JL, et al. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. *Clin Cancer Res* 2007;13:839–43.
- Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. *Breast Cancer Res* 2005;7:R93–100.
- Cybulski C, Wokońarczyk D, Kluźniak W, Kashyap A, Gołęb A, Soojewski M, et al. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles. *Br J Cancer* 2013;108:2601–9.
- Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. *J Natl Cancer Inst* 2007;99:929–35.
- Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. *Br J Cancer* 2011;105:1230–4.
- Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, et al. Germline BRCA1 mutations increase prostate cancer risk. *Br J Cancer* 2012;106:1697–701.
- Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *J Clin Oncol* 2013;31:1748–57.
- Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J, Clouston D, et al. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. *Cancer Prev Res* 2011;4:1002–10.
- Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S. Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers. *Prostate* 2016;76:1135–45.
- Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. *Am J Hum Genet* 2001;68:410–9.
- Walker R, Louis A, Berlin A, Horsburgh S, Bristow RG, Trachtenberg J. Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. *Can Urol Assoc J* 2014;8:E783–8.
- Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations. *Prostate* 2014;74:1444–51.
- Laitman Y, Keinan Boker L, Lipshitz I, Weissglas-Volkov D, Litz-Philipsborn S, Schayek H, et al. Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat* 2015;150:631–5.
- Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, et al. Cancer incidence in first- and second-degree relatives of BRCA1 and BRCA2 mutation carriers. *Oncologist* 2016;21:869–74.
- Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. *Nat Commun* 2017;8:13671.
- Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. *Nat Genet* 2018;50:645–51.
- Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. *Cell* 2015;161:1215–28.
- Rebbek TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffo L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA* 2015;313:1347–61.
- Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. *Nat Genet* 1995;11:428–33.
- Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. *Nat Genet* 1997;15:103–5.
- Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA* 2017;317:2402–16.
- Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulos A, et al. APC mutations in sporadic colorectal tumors: a mutational "hotspot" and interdependence of the "two hits". *Proc Natl Acad Sci U S A* 2000;97:3352–7.
- Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, et al. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. *Proc Natl Acad Sci U S A* 2007;104:4036–41.
- Krampitz GW, Norton JA. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. *Cancer* 2014;120:1920–31.
- Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. *J Clin Oncol* 2004;22:735–42.
- Roed Nielsen H, Petersen J, Therkildsen C, Skytte AB, Nilbert M. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2. *Acta Oncol* 2016;55:38–44.
- Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE, et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Res* 2007;9:104.
- Claes K, Vandesompele J, Poppe B, Dahan K, Coene I, De Paep A, et al. Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5' end of the BRCA1 gene. *Oncogene* 2002;21:4171–5.
- Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. *Am J Hum Genet* 2004;75:535–44.
- Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, et al. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. *Hum Mutat* 2006;27:1122–8.
- PFam v.31.0; 2017. Available from: <https://pfam.xfam.org>
- Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. *Hum Mol Genet* 2002;11:2805–14.
- Mikaelsdóttir EK, Valgeirsdóttir S, Eyfjord JE, Rafnar T. The Icelandic founder mutation BRCA2 999del5: analysis of expression. *Breast Cancer Res* 2004;6:R284–90.
- Buisson M, Anczukow O, Zetoune AB, Ware MD, Mazoyer S. The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. *Hum Mutat* 2006;27:1024–9.
- Brzovic PS, Rajagopal P, Hoyt DW, King MC, Kleit RE. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. *Nat Struct Biol* 2001;8:833–7.
- Bienstock RJ, Darden T, Wiseman R, Pedersen L, Barrett JC. Molecular modeling of the amino-terminal zinc ring domain of BRCA1. *Cancer Res* 1996;56:2539–45.
- Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, et al. Identification of a RING protein that can interact *in vivo* with the BRCA1 gene product. *Nat Genet* 1996;14:430–40.
- Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. *FASEB J* 1997;11:68–76.
- Williams RS, Green R, Glover JN. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. *Nat Struct Biol* 2001;8:838–42.

46. Huyton T, Bates PA, Zhang X, Sternberg MJ, Freemont PS. The BRCA1 C-terminal domain: structure and function. *Mutat Res* 2000;460:319–32.
47. Palacios IM. Nonsense-mediated mRNA decay: from mechanistic insights to impacts on human health. *Brief Funct Genom* 2013;12:25–36.
48. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. *J Am Stat Assoc* 1989;84:1074–8.
49. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J Roy Stat Soc B* 1995;57:289–300.
50. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, et al. Role of genetic testing for inherited prostate cancer risk: philadelphia prostate cancer consensus conference 2017. *J Clin Oncol* 2017;36:414–24.
51. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *Eur Urol* 2014;66:489–99.
52. Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjord JE, et al. BRCA2 mutation in Icelandic prostate cancer patients. *J Mol Med* 1997;75:758–61.
53. Gudmundsson J, Johannesdottir G, Berghthorsson JT, Arason A, Ingvarsson S, Egilsson V, et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. *Cancer Res* 1995;55:4830–2.
54. Barkardottir RB, Sarantaus L, Arason A, Vehmanen P, Bendahl PO, Kainu T, et al. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. *Eur J Hum Genet* 2001;9:773–9.
55. Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. *Crit Rev Oncol Hematol* 2007;61:153–61.
56. Cavanagh H, Rogers KM. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. *Hered Cancer Clin Pract* 2015;13:16.